ocular hypertension and glaucoma
Conditions
Interventions
None listed
Sponsors
Miyata Eye Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: People who have been treated with prostaglandin analog alone for ocular hypertension or glaucoma and are necessary to add brimonidine.
Exclusion criteria
Exclusion criteria: 1. People who have used intraocular pressure lowering drugs other than prostaglandin analog. 2. The use of antibacterial drug within three months from the initiation of brimonidine. 3. The use of eye drops with BAC within three months from the initiation of brimonidine. 4. People who have active ocular infection. 5. People who have severe underlying medical problems or complications. 6. People who are judged as improper for this study from the investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The species of the bacteria and the sensitivity of staphylococcus epidermidis isolated from the conjunctiva before and one year after the addition of brimonidine. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. The transition of the species of the bacteria and the sensitivity of staphylococcus epidermidis isolated from the conjunctiva. 2. The transition of the expression of gene of qacA/B, C/D from the isolated staphylococcus epidermidis. 3. The antibacterial effect of 0.1% brimonidine on the isolated staphylococcus epidermidis. | — |
Countries
Japan
Contacts
Public ContactTakuya Iwasaki
Miyata Eye Hospital Ophthalmology
Outcome results
None listed